atg7 (Cell Signaling Technology Inc)
Cell Signaling Technology Inc is a verified supplier 
Cell Signaling Technology Inc manufactures this product 
86
Structured Review
Cell Signaling Technology Inc
atg7
Atg7, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atg7/pm41950919-610-22-23
Average 86 stars, based on 1 article reviews
Atg7, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/atg7/pm41950919-610-22-23
Average 86 stars, based on 1 article reviews
atg7 - by Bioz Stars,
2026-09
86/100 stars
Images
Related Articles
other:Article Title: Copper potentiates PUFA-mediated antitumor activity by activating Lipophagy. Article Snippet: Polyunsaturated fatty acids (PUFAs) have demonstrated promising anticancer properties by inducing cancer cell death and inhibiting cancer metastasis.. As dynamic organelles, lipid droplets (LDs) may protect cells from PUFAinduced lipotoxicity by sequestering excess fatty acids.. However, the underlying mechanisms regulating LDs dynamics in PUFA-mediated tumor cytotoxicity remain poorly understood. Western Blot:Article Title: Effect of reticulocalbin 3 on monocyte-to-macrophage differentiation in sepsis through modulating autophagy Article Snippet: .. The samples were subjected to Western blotting with specific antibodies against RCN3 (Sigma, #HPA050402), LC3B (NOVUS, #NB100-2220, USA), and Article Title: Geniposide ameliorates ferroptosis through the ROS/p38 MAPK/NCOA4/GPX4-mediated ferritinophagy in a co-culture system of HMC3 and SH-SY5Y cells. Article Snippet: .. The antibodies used for immunoblotting were as follows: LC3B, p62, Incubation:Article Title: Species-specific cleavage of the autophagy adaptor p62 dictates responses to TNF. Article Snippet: REAGENT or RESOURCE SOURCE IDENTIFIER HALO image analysis platform v3.6.4134.263 Indica Labs https://indicalab.com/halo/ Area Quantification v2.4.2 algorithm Indica Labs https://indicalab.com/halo/ CytoNuclear v2.0.9 algorithm (HALO) Indica Labs https://indicalab.com/halo/ CRISPOR Concordet et al.59 https://crispor.gi.ucsc.edu Image Lab Touch Software v. 2.4.0.03 BioRad https://www.bio-rad.com ImageJ64 software ImageJ https://imagej.net/ij/ Incucyte Software v. 2024B Sartorius https://www.sartorius.com/en/products/ live-cell-imaging-analysis/live-cellanalysis-software/incucyte-softwarev2024b Other Orbitrap FusionTM LumosTM TribridTM Mass Spectrometer Thermo Fisher Scientific Cat# IQLAAEGAAPFADBMBHQ Easy-nLC 1200 LC System Thermo Fisher Scientific Cat# LC140 50 cm Emitters CoAnn Technologies Cat# ICT36007508-50 ABIRD - The Active Background Ion Reduction Device for nanospray LC/MS ESI Solutions Cat# ABIRD ll OPEN ACCESS Article e5 Molecular Cell 86, 1–13.e1–e11, April 16, 2026 membranes (Merck). .. Membranes were blocked with BSA 5% in TBST for 30 min and incubated with the following primary antibodies overnight (all 1:1000 dilution): Article Title: Structure-based discovery of a novel allosteric activator of ATG4B for the treatment of triple-negative breast cancer. Article Snippet: Triple-negative breast cancer (TNBC) is highly malignant and lacks effective therapeutic drugs.. ATG4B, a critical cysteine protease in autophagy, regulates LC3B processing and recycling to promote autophagosome formation, and its activation represents a promising therapeutic strategy for cancer.. Based on structure-based drug design, this study conducted virtual screening of the SPECS compound library and optimized the structure through structure-activity relationship analysis, obtaining a novel ATG4B allosteric activator, 16a. Membrane:Article Title: Structure-based discovery of a novel allosteric activator of ATG4B for the treatment of triple-negative breast cancer. Article Snippet: Triple-negative breast cancer (TNBC) is highly malignant and lacks effective therapeutic drugs.. ATG4B, a critical cysteine protease in autophagy, regulates LC3B processing and recycling to promote autophagosome formation, and its activation represents a promising therapeutic strategy for cancer.. Based on structure-based drug design, this study conducted virtual screening of the SPECS compound library and optimized the structure through structure-activity relationship analysis, obtaining a novel ATG4B allosteric activator, 16a. Blocking Assay:Article Title: Structure-based discovery of a novel allosteric activator of ATG4B for the treatment of triple-negative breast cancer. Article Snippet: Triple-negative breast cancer (TNBC) is highly malignant and lacks effective therapeutic drugs.. ATG4B, a critical cysteine protease in autophagy, regulates LC3B processing and recycling to promote autophagosome formation, and its activation represents a promising therapeutic strategy for cancer.. Based on structure-based drug design, this study conducted virtual screening of the SPECS compound library and optimized the structure through structure-activity relationship analysis, obtaining a novel ATG4B allosteric activator, 16a. |